NPCE (Neuropace, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by NPCE officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-04 | Joel Becker | CHIEF EXECUTIVE OFFICER | F | — | — |
| 2026-08-28 | Martha Morrell | CHIEF MEDICAL OFFICER | F | — | — |
| 2026-08-28 | Joel Becker | CHIEF EXECUTIVE OFFICER | F | — | — |
| 2026-06-25 | Martha Morrell | CHIEF MEDICAL OFFICER | F | — | — |
| 2026-06-22 | Uri Geiger | Director | A | — | — |
| 2026-06-22 | Frank M Fischer | Director | A | — | — |
| 2026-06-22 | Rakhi Kumar | Director | A | — | — |
| 2026-06-05 | Renee Ryan | Director | A | — | — |
| 2026-06-05 | Rakhi Kumar | Director | A | — | — |
| 2026-06-05 | Uri Geiger | Director | A | — | — |
| 2026-06-05 | R Scott Huennekens | Director | A | — | — |
| 2026-06-05 | Lisa Andrade | Director | A | — | — |
| 2026-06-05 | Frank M Fischer | Director | A | — | — |
| 2026-06-04 | Joel Becker | CHIEF EXECUTIVE OFFICER | F | — | — |
| 2026-05-28 | Martha Morrell | CHIEF MEDICAL OFFICER | F | — | — |
| 2026-05-28 | Joel Becker | CHIEF EXECUTIVE OFFICER | F | — | — |
| 2026-05-19 | Joel Becker | CHIEF EXECUTIVE OFFICER | A | — | — |
| 2026-05-19 | Patrick F. Williams | Chief Financial Officer | A | — | — |
| 2026-05-19 | Martha Morrell | CHIEF MEDICAL OFFICER | A | — | — |
| 2026-03-25 | Martha Morrell | CHIEF MEDICAL OFFICER | F | — | — |
| 2026-03-24 | Uri Geiger | Director | A | — | — |
| 2026-03-24 | JOSEPH LACOB | Director | A | — | — |
| 2026-03-23 | Rakhi Kumar | Director | A | — | — |
| 2026-03-23 | Frank M Fischer | Director | A | — | — |
| 2026-03-04 | Joel Becker | CHIEF EXECUTIVE OFFICER | F | — | — |
| 2026-03-04 | Martha Morrell | CHIEF MEDICAL OFFICER | MIXED | — | — |
| 2026-03-02 | Martha Morrell | CHIEF MEDICAL OFFICER | F | — | — |
| 2026-03-02 | Joel Becker | CHIEF EXECUTIVE OFFICER | F | — | — |
| 2026-02-23 | Martha Morrell | CHIEF MEDICAL OFFICER | F | — | — |
| 2025-12-23 | Uri Geiger | Director | A | — | — |
| 2025-12-23 | Frank M Fischer | Director | A | — | — |
| 2025-12-23 | JOSEPH LACOB | Director | A | — | — |
| 2025-12-23 | Rakhi Kumar | Director | A | — | — |
| 2025-12-04 | Martha Morrell | CHIEF MEDICAL OFFICER | F | — | — |
| 2025-12-01 | Joel Becker | CHIEF EXECUTIVE OFFICER | F | — | — |
| 2025-12-01 | Martha Morrell | CHIEF MEDICAL OFFICER | F | — | — |
| 2025-11-24 | Martha Morrell | CHIEF MEDICAL OFFICER | F | — | — |
| 2025-09-22 | Rakhi Kumar | Director | A | — | — |
| 2025-09-22 | Uri Geiger | Director | A | — | — |
| 2025-09-22 | Frank M Fischer | Director | A | — | — |
| 2025-09-22 | JOSEPH LACOB | Director | A | — | — |
| 2025-09-04 | Martha Morrell | CHIEF MEDICAL OFFICER | F | — | — |
| 2025-08-28 | Martha Morrell | CHIEF MEDICAL OFFICER | F | — | — |
| 2025-08-28 | Joel Becker | CHIEF EXECUTIVE OFFICER | F | — | — |
| 2025-08-22 | Martha Morrell | CHIEF MEDICAL OFFICER | F | — | — |
| 2025-06-24 | Patrick F. Williams | Chief Financial Officer | A | — | — |
| 2025-06-24 | JOSEPH LACOB | Director | A | — | — |
| 2025-06-24 | Uri Geiger | Director | A | — | — |
| 2025-06-24 | Frank M Fischer | Director | A | — | — |
| 2025-06-24 | Rakhi Kumar | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 4,451,485 | — |
| — | 10%+ Owner | 4,370,550 | — |
| — | Director | 4,042,657 | — |
| — | 10%+ Owner | 3,411,009 | — |
| — | 10%+ Owner | 3,272,199 | — |
| — | Director | 599,534 | — |
| — | Chief Executive Officer | 430,027 | — |
| — | Director | 142,928 | — |
| — | Chief Legal Officer/Secretary | 141,139 | — |
| — | CHIEF EXECUTIVE OFFICER | 138,000 | — |
| — | CHIEF FINANCIAL OFFICER | 131,613 | — |
| — | Chief Financial Officer | 68,670 | — |
| — | Director | 57,744 | — |
| — | CHIEF MEDICAL OFFICER | 51,692 | — |
| — | Director | 23,039 | — |
| — | Director | 2,890 | — |
| — | Director | 2,890 | — |
| — | Director | 2,890 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the NPCE quote page; the site-wide leaderboard is on the insider transactions hub.